Cassava Sciences Inc (SAVA) concluded trading on Tuesday at a closing price of $2.36, with 3.83 million shares of worth about $9.03 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -79.98% during that period and on December 31, 2024 the price saw a loss of about -1.67%. Currently the company’s common shares owned by public are about 47.98M shares, out of which, 41.80M shares are available for trading.
Stock saw a price change of -2.07% in past 5 days and over the past one month there was a price change of -38.54%. Year-to-date (YTD), SAVA shares are showing a performance of -89.52% which decreased to -89.52% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $2.23 but also hit the highest price of $42.20 during that period. The average intraday trading volume for Cassava Sciences Inc shares is 5.24 million. The stock is currently trading -12.04% below its 20-day simple moving average (SMA20), while that difference is down -84.15% for SMA50 and it goes to -88.52% lower than SMA200.
Cassava Sciences Inc (NASDAQ: SAVA) currently have 47.98M outstanding shares and institutions hold larger chunk of about 29.68% of that.
The stock has a current market capitalization of $111.65M and its 3Y-monthly beta is at -1.00. It has posted earnings per share of -$1.37 in the same period. It has Quick Ratio of 3.55 while making debt-to-equity ratio of 0.00. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for SAVA, volatility over the week remained 9.65% while standing at 9.28% over the month.
Stock’s fiscal year EPS is expected to rise by 62.79% while it is estimated to increase by 49.61% in next year.
Coverage by H.C. Wainwright stated Cassava Sciences Inc (SAVA) stock as a Buy in their note to investors on October 08, 2024, suggesting a price target of $116 for the stock. On July 01, 2024, H.C. Wainwright Downgrade their recommendations, while on November 16, 2022, B. Riley Securities Downgrade their ratings for the stock with a price target of $44. Stock get a Neutral rating from Cantor Fitzgerald on July 15, 2021.
